Kurt Farrugia

This week, ZenPharm, the Maltese joint venture with Canadian cannabis producer, Zenabis Global, received its Maltese licence to process cannabis for medicinal use and research purposes out of its Hal Far Industrial Estate premises.

Kurt Farrugia, CEO of Malta Enterprise – the national economic development agency that assisted the company to set up locally – considers this “an important milestone for Malta’s medical cannabis industry.”

“We are gaining momentum with the production of cannabis for medical use in Malta,” he wrote. “Zenabis – a Maltese joint venture and partner of Zenpharm, have received a licence for the production of medical cannabis in their facility in Hal Far, Malta.”

The CEO said that the issuing of the second licence for the production of cannabis for medical use shows that “Malta is becoming a centre of excellence in such an important emerging sector.”

“Those companies strive hard to achieve the Medicine’s Authority pharmaceutical standards. Now that they do, patients can rest assured that the Made in Malta product is top quality. A gold standard for the industry. This is indeed a proud moment.”

Through its licence, ZenPharm plans to ship around 500kg of cannabis out of Malta annually to EU countries, with the largest market being Germany.

Featured Image:

Kurt Farrugia / LinkedIn

Related

Charles Xuereb / Trident Estates Annual Report

Firms not offering flexibility find it difficult to recruit and retain employees, says Trident Estates CEO

30 May 2024
by Fabrizio Tabone

Charles Xuereb notes that the office environment has an impact on corporate culture and lifestyles tenants want to promote.

‘Technology is changing at a rapid pace, so staying at the forefront means we need to adapt’ – BMIT CEO

30 May 2024
by Helena Grech

As the leading local technology company shares its financial results for 2023, CEO Christian Sammut attests that forward-looking plans for ...

Medserv and Regis ‘have forged a powerful alliance,’ says CEO

30 May 2024
by Robert Fenech

The company is celebrating 50 years from the founding of Medserv

‘Past year was predominantly marked by growing competitive pressures,’ says Farsons CEO

30 May 2024
by Fabrizio Tabone

During the financial year ended 31st January 2024, Farsons Group’s pre-tax profit rose by 4.9% to €16.1 million.

Close Bitnami banner
Bitnami